undamentalytics Newsletter
Sign in

Korsana Biosciences, Inc. revenue

Korsana Biosciences, Inc.'s revenue was $2.1m in fiscal 2025, up 3.7% on the year before. Since fiscal 2019 ($4.5m) it has grown at a compound -12.1% a year. Over the last twelve months it was $1.9m.

Revenue history

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue4,5072,2963,94229702,0002,0741,900
Growth on the year before—−49.1%+71.7%−92.5%−100.0%—+3.7%—

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
License Agreement $1M 48.2% ▼ 42.9%
Purchase Agreement $800,000 38.6% —
Option Agreement $274,000 13.2% ▲ 9.6%

From Korsana Biosciences, Inc.'s 10-K filed March 30, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Korsana Biosciences, Inc. $1.9m -12.6% —
Seres Therapeutics, Inc. $1.9m 100.0% -75.6%
Ovid Therapeutics Inc. $1.6m -76.2% 99.8%
Absci Corp $1.6m -62.3% -43.3%
Collplant Biotechnologies Ltd $2.4m 360.4% —
Korro Bio, Inc. $2.4m -62.1% -53.7%

Compare with peers

Head to head: KRSA vs MCRBKRSA vs OVIDABSI vs KRSACLGN vs KRSA

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Korsana Biosciences, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Korsana Biosciences, Inc.